Key result
Incretin-based therapy in HFrEF patients reduced body weight by 13.44 kg, BMI by 4.19 kg/m², HbA1c by 0.32%, and eGFR by 9.00 mL/min/1.73 m² over 239 days.
Why the study?
Does incretin-based therapy (tirzepatide or semaglutide) improve metabolic and cardiorenal parameters in patients with HFrEF (LVEF <50%) receiving foundational medical therapy?
Cohort (n=34)
Open-label
No
Does incretin-based therapy (tirzepatide or semaglutide) improve metabolic and cardiorenal parameters in patients with HFrEF (LVEF <50%) receiving foundational medical therapy?
Answers are grounded in this paper and cite their sources.
In a small real-world cohort of patients with HFrEF on foundational therapy, incretin-based therapy (mostly tirzepatide) significantly reduced body weight, BMI, and HbA1c without changing NT-proBNP or heart rate, though eGFR declined and several ICD-related hospitalizations occurred.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lozo et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=34). Incretin-based therapy (tirzepatide or semaglutide) vs. Baseline (pre-treatment) was evaluated on Change in body weight from baseline to follow-up (6-9 months) (MD -13.44 kg, p=<0.001). Incretin-based therapy in HFrEF patients reduced body weight by 13.44 kg, BMI by 4.19 kg/m², HbA1c by 0.32%, and eGFR by 9.00 mL/min/1.73 m² over 239 days.
Synapse has enriched 10 related papers. Consider them for comparative context: